Contera Pharma identifies and develops innovative treatments for patients suffering from movement disorders. We use our expertise in drug discovery and development in close collaboration with expert individuals and organizations to provide foundations for success.
The lead project JM-010 is approved for Phase IIa clinical trials for treatment of dyskinesia associated with Parkinson's disease.
Contera Pharma is an affiliate of Bukwang Pharma. Co., Ltd. in South Korea.